Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HK1 | P19367 | 1/20 | 0.50 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601168 | 0.82 | MAP4K4 (0.53) | ALDH1A1MAPTRAB9AHPGDCSNK2A1 | |
| SCHEMBL17632161 | 0.82 | CSNK2A1 (0.59) | ALDH1A1MAPTRAB9ACSNK2A1NPC1 | |
| SCHEMBL69900 | 0.81 | CSNK2A1 (0.62) | ALDH1A1MAPTRAB9ACSNK2A1NPC1 | |
| Bromide SCHEMBL12496053 | 0.80 | CSNK2A1 (0.57) | ALDH1A1MAPTRAB9ACSNK2A1NPC1 | |
| Hydrochloric Acid SCHEMBL11145599 | 0.80 | CSNK2A1 (0.61) | ALDH1A1MAPTRAB9ACSNK2A1NPC1 | |
| Bromide SCHEMBL22834317 | 0.80 | CSNK2A1 (0.61) | ALDH1A1MAPTRAB9ACSNK2A1NPC1 | |
| SCHEMBL2406426 | 0.79 | CSNK2A1 (0.49) | ALDH1A1MAPTRAB9ACSNK2A1NPC1 | |
| SCHEMBL2407377 | 0.79 | NPC1 (0.44) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29393032 | 0.79 | KDM4E (0.54) | ALDH1A1MAPTRAB9ACSNK2A1NPC1 | |
| SCHEMBL9954813 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MAPTRAB9AHPGDCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2032138-A2 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | Merck Sharp & Dohme Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007141571-A2 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141571-A2 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MAPT, MARK4, MARK3 | ALDH1A1 3884/4885MAPT 1/4885RAB9A 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.